Chemotherapy News and Research

Latest Chemotherapy News and Research

myeloMATCH program opens enrollment for acute myeloid leukemia and MDS

Four leading cancer research organizations in the United States and Canada announce the opening of patient enrollment to myeloMATCH, a unique portfolio of clinical trials to test precision medicine treatments for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

23 Oct 2024

HER2-postive breast cancer drugs show promise for bile duct cancer treatment

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

23 Oct 2024

3D-printed model created to mimic cancer metastasis

Scientists have created a 3D-printed model to mimic the specific conditions that spur the spread of cancer cells.

23 Oct 2024

Multigene RNA signature enhances treatment strategies for triple negative breast cancer

Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise as a way to improve disease-free survival, finds a clinical trial published by The BMJ today.

23 Oct 2024

New drug WNTinib shows promise in treating pediatric liver cancer

A new drug called WNTinib can delay the growth of tumors and improve survival in hepatoblastoma, a type of liver cancer that occurs in young children.

22 Oct 2024

Tissue stiffening linked to disease progression in HER2-negative breast cancer

A study published in Clinical Cancer Research confirmed that tissue stiffening in the most common types of breast cancer, HER2-negative, can directly cause disease progression and metastasis, leading to detrimental outcomes for patients.

22 Oct 2024

Physical tests offer prognostic insights for lung cancer patients

A study of patients with metastatic lung cancer by researchers based in Brazil and the United States has found that their performance in simple physical tests such as sitting down, standing and walking can help physicians arrive at a prognosis and approach to treatment.

22 Oct 2024

MRI can spare many patients with rectal cancer from invasive surgery

Magnetic resonance imaging (MRI) can spare many patients with rectal cancer from invasive surgery that can carry lifelong side effects, new research indicates.

22 Oct 2024

Study reveals complex role of polyploidy in cancer and treatment resistance

Polyploidy is a state where a cell contains more copies of the genetic material than the usual "diploid" cell, which contains two copies.

21 Oct 2024

Unraveling the mechanisms of B-cell maturation in blood cancer

Over four hundred people, 80% of them being children under 14 years old, will be diagnosed with B-cell Acute Lymphoblastic Leukaemia (B-ALL) next year in Spain, according to the latest projections from the Spanish network of cancer registries (REDECAN).

21 Oct 2024

Aerobic exercise boosts cognitive function in breast cancer patients

Many women who receive chemotherapy experience a decreased ability to remember, concentrate, and/or think-;commonly referred to as "chemo-brain" or "brain fog"-;both short- and long-term.

21 Oct 2024

Polyploidy can be a double-edged sword in cancer

Polyploidy is a state where a cell contains more copies of the genetic material than the usual "diploid" cell, which contains two copies.

21 Oct 2024

Scientists reveal how miRNAs shape cancer and offer new paths for treatment

Review explores how microRNAs (miRNAs) interact in cancer development, their potential in diagnosis, and innovative therapeutic strategies, including overcoming chemotherapy resistance.

20 Oct 2024

Studies reveal the financial fallout of cancer survivors

A diagnosis of cancer can take a toll on more than a person's health. Researchers at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston found that financial fallout can follow patients with cancer and their families in the form of bankruptcy, lower credit scores, and other forms of financial challenges years after a cancer diagnosis.

18 Oct 2024

New combination treatment authorized for unresectable urothelial cancer patients

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy.

18 Oct 2024